Gennex Laboratories Ltd
BSE:531739
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Gennex Laboratories Ltd
BSE:531739
|
2.9B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
965.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
594B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
105.9B EUR |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Gennex Laboratories Ltd
Glance View
Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing of bulk drugs, intermediaries and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which caters to both domestic and international markets.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Gennex Laboratories Ltd is 28%, which is below its 3-year median of 38.5%.
Over the last 3 years, Gennex Laboratories Ltd’s Gross Margin has decreased from 34.2% to 28%. During this period, it reached a low of 28% on Oct 30, 2025 and a high of 53.1% on Sep 30, 2023.
